Abstract
AMAÇ: Multipl Sklerozda (MS) monoklonal antikorlar gibi birçok yeni tedavi vardır. Bu olgu ile Alemtuzumab tedavisinin önemli bir yan etkisini bildirmeyi amaçladık.
OLGU: 32 yaşında kadın MS hastası alemtuzumab infüzyonu aldı. İlk doz sonrası yapılan kan testlerinde hayati tehlikeye neden olabilen karaciğer enzimlerinde 17 kat artış tespit edildi. Bu durum geçici hücre aktivasyonundan ve İnfüzyonla İlişkili Reaksiyonlardan (IAR'ler) kaynaklandığı düşünüldü.
SONUÇLAR: Monoklonal antikor tedavilerinin yan etkileri bilinmekle birlikte bu durumun fatal olabileceği her zaman akılda tutulmalı, gerekli önlemler alınmalıdır
Supporting Institution
bulunmamaktadır
Project Number
bulunmamaktadır
Thanks
Bulunmamamktadır
References
- (1) Havla J, Warnke C, Derfuss T, Kappos L, Hartung H-P, Hohlfeld R. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Ärzteblatt International, 2016;13(51-52):879-86. https://doi: 10.3238/arztebl.2016.0879.
- (2) Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J et al. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol, 2017; 98(3):254-62. https://doi: 10.1111/ejh.12825.
- (3) Thomas K, Eisele J, Rodriguez-Lea FA, Hainke U, Ziemssen T. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm, 2016; 3(3): e228. https://doi: 10.1212/NXI.0000000000000228
- (4) Sandra Vukusic S, Brassat D, Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C. Single-Arm Study to Assess Comprehensive Infusion Guidance for the Prevention and Management of the Infusion Associated Reactions (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Alemtuzumab (EMERALD) Mult Scler. Relat. Disord. 2019; 29:7-14 doi: https://doi.org/10.1016/j.msard.2019.01.019
- (5) Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014;10:124(2):188-5. https://doi: 10.1182/blood-2014-05-552729.
Abstract
There are many new treatments in Multiple Sclerosis (MS), such as monoclonal antibodies. We
aimed to report the expected but crucial side effects of alemtuzumab treatment for the first time.
A 32 years old female with MS had been received alemtuzumab; after therapy, 17-times increase
of liver enzymes called fatal level was detected in blood tests. It could be caused by transient
cell activation and infusion associated reactions (IARs). The side effects of monoclonal antibody
treatments can be fatal to the patient, even if known.
Project Number
bulunmamaktadır
References
- (1) Havla J, Warnke C, Derfuss T, Kappos L, Hartung H-P, Hohlfeld R. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Ärzteblatt International, 2016;13(51-52):879-86. https://doi: 10.3238/arztebl.2016.0879.
- (2) Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J et al. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol, 2017; 98(3):254-62. https://doi: 10.1111/ejh.12825.
- (3) Thomas K, Eisele J, Rodriguez-Lea FA, Hainke U, Ziemssen T. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm, 2016; 3(3): e228. https://doi: 10.1212/NXI.0000000000000228
- (4) Sandra Vukusic S, Brassat D, Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C. Single-Arm Study to Assess Comprehensive Infusion Guidance for the Prevention and Management of the Infusion Associated Reactions (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Alemtuzumab (EMERALD) Mult Scler. Relat. Disord. 2019; 29:7-14 doi: https://doi.org/10.1016/j.msard.2019.01.019
- (5) Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014;10:124(2):188-5. https://doi: 10.1182/blood-2014-05-552729.
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Case study |
| Authors | |
| Project Number | bulunmamaktadır |
| Publication Date | November 1, 2021 |
| Acceptance Date | November 4, 2021 |
| Published in Issue | Year 2021 Volume: 4 Issue: 3 |
All site content, except where otherwise noted, is licensed under a Creative Common Attribution Licence. (CC-BY-NC 4.0)
